rexresearch.comDr. Vladimir KHAVINSON
Epitalin ( Ala-Glu-Asp-Gly ) Tetrapeptide Therapy
Epitalin ( Ala-Glu-Asp-Gly ) Tetrapeptide Therapy
https://www.youtube.com/watch?v=ff4_udTVivg
https://youtu.be/ff4_udTVivg
Introducing the Peptide Revolution
Dr. Vladimir Khavinson
https://nootropix.com/epitalon-fountain-of-youth/
Epitalon: The Fountain of Youth
by Dirk Wright
by Dirk Wright
...Dr. Khavinson found that introducing epithalamin into mammals resulted in a reversal of age related diseases, and a reversal of the signs of aging. He was able to take geriatric female mice, who were no longer fertile, give them epithalamin, and after about two weeks of treatment, the mice became fertile again, got pregnant and had pups.[4] He showed that Epitalon induces telomerase activity in human somatic cells, proving that telomeres were lengthened by the peptide.[5] The synthetic version of epithalamin was patented by Dr. Khavinson and called “Epitalon” (also sometimes called epithalon since the original word is in Russian). It was approved for general use in the Soviet Union in 1990 and has been used in gerontology there ever since. No adverse side effects have ever been reported, according to Dr. Khavinson.
Since Epitalon is patented and trademarked, no drug company will research it. Since drug companies pay for almost all of the research on new medicines, no human clinical trials have been done in the West on it. Almost all of the research has been done by Dr. Khavinson and his associates. The results of his research are startling: for example, the application of Epithalamin diminished mortality in aged humans by 1.8 times over a 6 year period of observation. [6] Here in the West, Epitalon is sold as a research chemical, not approved by the FDA for any purpose, but unregulated for research purposes. Anyone who uses it is considered a “researcher,” in other words.
Epitalon is a small peptide of 4 amino acids: Ala-Glu-Asp-Gly and can be administered via injection, as a nasal spray, or through the skin. The most effective route of administering it is via injection, either subcutaneously or intramuscularly. The peptide is typically given 2-3 times a day for 10-20 days in doses of 5-10 mg each. This cycle is repeated once every six to twelve months, but Epitalon can be given as often as desired. There are no negative side effects from the drug ever reported in over 100 studies on the peptide and from clinical use in Russia since 1990. Epitalon works mainly on the endocrine system but has effects on the entire body.[7]
When I first started taking it, my sense of smell returned, my digestion improved and I slept better. I have also noted positive changes in my vision and hearing. All of these functions are related to the autonomic nervous system and the endocrine system. Epitalon has been shown to restore normal melatonin production in aging monkeys, as well as restore the normal circadian rhythm for cortisol production, both of which result in better sleep at night.[8]
https://nootropix.com/epitalon-mechanism-action/
Epitalon, Part II: Mechanism of Action
...Epitalon is a synthetic peptide which were originally developed based upon the action of epithalamin, a hormone produced by the pineal gland. This hormone was found to stimulate the production of telomerase, an enzyme which plays a role in maintaining telomere length. Telomeres are non-coding terminal regions of DNA strands which preserve the integrity of the strand. With each revision, telomeres are shortened until the DNA strand cannot be further replicated. This process is highly implicated in the ageing process. Elongating telomeres theoretically extend the lifespan of a copy of DNA and allows it to replicate more times than usual. This was the theory behind the development of Epitalon®, a synthetic version of epithalamin which also stimulates the production of telomerase. Indeed, this theory has been confirmed in vitro in human cell cultures[1]...
Neutralisation of Harmful Free Radicals... Inhibition of Cancer Formation & Growth ... Attenuation of Inflammation ... Endocrine Regulation
https://www.ncbi.nlm.nih.gov/pubmed/575333
Exp Pathol (Jena). 1979;17(9):539-45.
Increase in lifespan of rats following
polypeptide pineal extract treatment.
Dilman VM, Anisimov VN, Ostroumova MN, Khavinson VK, Morozov VG.
Dilman VM, Anisimov VN, Ostroumova MN, Khavinson VK, Morozov VG.
Abstract
The 20 month-long treatment of female rats with daily doses of 0.1 or 0.5 mg of polypeptide pineal extract (PPE) per animal increased their lifespan by 10 and 25%, respectively, as compared with controls. At the age of 16--18 months, 38% of control rats exhibited persistent disturbances in estral function (constant estrus or repeated pseudogestations), whereas these disorders were observed in 7% of experimental animals only. After administration of PPE to 16--18 month-old female rats checked for sterility by a two-week mating, a second mating period resulted in gestation development in four out of 16 animals and deliveries, accordingly. While chronic treatment with PPE did not affect the rate of neoplasm incidence, the mean age of tumour detection in the control group was 697 days and in experimental groups it was 811 and 868 days, respectively. Certain aspects of the interrelationship of rate of ageing, lifespan and specific age pathology are discussed.
http://www.ncbi.nlm.nih.gov/pubmed/12937682
Bull Exp Biol Med. 2003 Jun;135(6):590-2.
Epithalon peptide induces telomerase
activity and telomere elongation in human somatic cells.
Khavinson VKh1, Bondarev IE, Butyugov AA.
Khavinson VKh1, Bondarev IE, Butyugov AA.
Abstract
Addition of Epithalon peptide in telomerase-negative human fetal fibroblast culture induced expression of the catalytical subunit, enzymatic activity of telomerase, and telomere elongation, which can be due to reactivation of telomerase gene in somatic cells and indicates the possib
http://www.nel.edu/userfiles/articlesnew/NEL220401A03.pdf?route=22_4/NEL220401A03_Khavinson_w.pdf
Synthetic tetrapeptide epitalon restores
disturbed neuroendocrine regulation in senescent monkeys
Vladimir Khavinson, Nadezhda Goncharova & Boris Lapin
Vladimir Khavinson, Nadezhda Goncharova & Boris Lapin
https://www.ncbi.nlm.nih.gov/pubmed/14523363
Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):233-40.
Peptides of pineal gland and thymus prolong
human life.
Khavinson VKh1, Morozov VG.
AbstractKhavinson VKh1, Morozov VG.
OBJECTIVES AND DESIGN:
Researchers of the St. Petersburg Institute of Bioregulation and Gerontology of the North-Western Branch of the Russian Academy of Medical Sciences and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences (Kiev) clinically assessed the geroprotective effects of thymic (Thymalin) and pineal (Epithalamin) peptide bioregulators in 266 elderly and older persons during 6-8 years. The bioregulators were applied for the first 2-3 years of observation.
RESULTS:
The obtained results convincingly showed the ability of the bioregulators to normalize the basic functions of the human organism, i.e. to improve the indices of cardiovascular, endocrine, immune and nervous systems, homeostasis and metabolism. Homeostasis restoration was accompanied by a 2.0-2.4-fold decrease in acute respiratory disease incidence, reduced incidence of the clinical manifestations of ischemic heart disease, hypertension disease, deforming osteoarthrosis and osteoporosis as compared to the control. Such a significant improvement in the health state of the peptide-treated patients correlated with decreased mortality rate during observation: 2.0-2.1-fold in the Thymalin-treated group; 1.6-1.8-fold in the Epithalamin-treated group; 2.5-fold in the patients treated with Thymalin plus Epithalamin as compared to the control. A separate group of patients was treated with Thymalin in combination with Epithalamin annually for 6 years and their mortality rate decreased 4.1 times as compared to the control.
CONCLUSIONS:
The obtained data confirmed the high geroprotective efficacy of Thymalin and Epithalamin and the expediency of their application in medicine and social care for health maintenance and age-related pathology prevention in persons over 60 to prolong their active longevity.
https://worldwide.espacenet.com/advancedSearch?locale=en_EP
Patents
PEPTIDE EXHIBITING STRESS
PROTECTIVE ACTION, PHARMACEUTICAL COMPOSITION BASED THEREON
AND USE THEREOF
UA92387
The invention relates to a medicinal agent peptide
glutamyl-aspartyl-glycine with general formula H-GIu-
Asp-Gly-OH sequence 1 [SEQ ID NO:1] exhibiting stress
protective action for prevention and treatment of functional or
stress induced disorders, which occur as a result of extreme
impacts.UA92387
PEPTIDE CAPABLE OF ENHANCING CAPILLARIES
RESISTANCE, PHARMACEUTICAL COMPOSITION BASED THEREON AND
METHOD OF USE THEREOF
UA91137
The invention is related to the medicinal means of
correction of metabolic vascular syndrome and diseases, associated
with disordered vascular wall permeability and capillaries
fragility, and can be used as a means of enhancing capillaries
resistance. There is proposed a peptide lysyl-glutamyl-asparagine
acid of the general formula H-Lys-Glu-Asp-OH sequence 1
[SEQ ID NO:1], revealing biological activity and capable of
enhancing capillaries resistance.UA91137
PEPTIDE CAPABLE OF STIMULATING THE
REGENERATION OF NEURONS, PHARMACEUTICAL COMPOSITION BASED
THEREON AND METHOD OF USE THEREOF
UA91136
The invention is related to the medicinal means of
treatment of diseases, traumas, as well as consequences of traumas
of the central nervous system, and can be also used as a means of
stimulating neurons regeneration. There is proposed a peptide glutamyl-aspartyl-arginine
with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1]
capable of stimulating the regeneration of neurons.UA91136
PEPTIDE REVEALING AN IMMUNOGEROPROTECTIVE
EFFECT, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHOD OF
USE THEREOF
UA91135
The invention is related to the medicinal means of
prevention and correction of age-related disorders of cellular and
humoral immunity and may be used as a medication revealing an
immunogeroprotective effect.UA91135
Peptide Substance Restoring Myocardium
Function
US7662789
The invention refers to the pharmaceutical means for the treatment
of cardiovascular diseases and can be used as a substance
restoring myocardium function in the course of treatment for
different forms of this pathology. There is proposed a new
tetrapeptide alanyl-glutamyl-aspartyl-arginine with general
formula: Ala-Glu-Asp-Arg sequence 1 [SEQ ID NO:1], revealing
biological activity, which is manifested in the restoration of the
myocardium function. There is proposed a pharmacological substance
containing an effective amount of tetrapeptide
alanyl-glutamyl-aspartyl-arginine with general formula:
Ala-Glu-Asp-Arg sequence 1 [SEQ ID NO:1] as an active peptide
agent, revealing biological activity, which is manifested by the
restoration of myocardium function. Being included in the
medication, this substance contributes to the restoration of the
myocardium function...US7662789
Peptide Substance Restoring Respiratory
Organs Function
US7625870
The invention refers to the medicinal remedies for
respiratory system diseases treatment and may be applied as a
substance, capable of restoring respiratory organs functions and
used for treatment of different forms of lung pathology. There is
proposed a biologically active new tetrapeptide
alanyl-glutamyl-aspartyl-leucine of the general formula
Ala-Glu-Asp-Leu, capable of restoring respiratory organs function.
There is proposed a pharmaceutical substance, containing as an
active peptide agent an effective amount of tetrapeptide
alanyl-glutamyl-aspartyl-leucine of the general formula
Ala-Glu-Asp-Leu, which if used in the medical preparation
contributes to the restoration of the respiratory organs function.US7625870
Method of treating complications in
immunodepressed states resulting from HIV infection
US6368788
Methods of treatment of subjects for decreasing cell
mediated autoimmunity or humoral autoimmunity by administering an
R'-Glu-Trp-R'' pharmaceutical preparation useful in
subjects having autoimmune diseases.US6368788
Tetrapetide revealing geroprotective
effect, pharmacological substance on its basis, and the method
of its application
US5728680 // US6727227
Tetrapeptide L-alanyl-L-glutamyl-L-aspartyl-glycine (SEQ
ID NO: 1) of the general formula L-Ala-L-Glu-L-Asp-Gly (SEQ ID NO:
1) is proposed as a biologically active compound with a
geroprotective effect. The use of L-Ala-L-Glu-L-Asp-Gly (SEQ ID
NO: 1) tetrapeptide in medicine is proposed for preparing a
substance displaying a geroprotective effect. There is proposed a
pharmacological substance, which contains as its active base an
effective amount of tetrapeptide of the formula L-alanyl-L-glutamyl-L-aspartyl-glycine
(L-Ala-L-Glu-L-Asp-Gly) (SEQ ID NO: 1) or its salts of the
amino group (acetate, hydrochloride, oxalate) and of carboxyl
groups (the salts of metals-Sodium, Potassium, Calcium, Lithium,
Zinc, Magnesium, and also the salts of organic and inorganic
cations-ammonium and triethylammonium). The substance is proposed
for parenteral, intranasal, oral administration, and local
application. With respect to the invention, the method of
premature ageing prevention involves prophylactic and/or
therapeutic administration to a patient of the pharmacological
substance in doses of 0.01 to 100 mug/kg of the body weight at
least once a day for a period necessary for the achievement of a
therapeutic effect.US5728680 // US6727227
Pharmaceutical lysine-containing
polypeptide compositions and methods of use thereof
US6066622 // US6346514
Pharmaceutical compositions and methods are provided for
the therapy of immunodeficient, immunodepressed or hyperactive
immune states and for the prevention and treatment of
opportunistic infections in such states comprising administering
to a subject a pharmaceutically acceptable composition comprising
as an active ingredient peptides having the formula R'-L-Glx-L-Glx-L-Lys-R''
and/or their pharmaceutically acceptable salts; wherein Glx is Gln
or Glu.US6066622 // US6346514
Use of a dipeptide for stimulating repair
processes
US6642201
L-Lys-L-Glu dipeptide is proposed for use in
medicine for preparation of a drug capable of stimulating repair
processes. According to the invention, the pharmaceutical peptide
preparation capable of stimulating regeneration consists of
pharmaceutically admissible carrier and effective quantity of
dipeptide as an active part, which is a combination of,
L-lysil-L-glutamic acid or its salts.The pharmaceutical peptide
preparation is proposed for parenteral, intranasal oral and local
application.According to the invention, the method stimulating
regeneration consists of prophylactic and/or treatment injections
of the drug in the dose of 0.01-100 mukg per per 1 kg of weight,
at least once a day during a period necessary for obtaining a
therapeutic effect.US6642201
Pharmaceutical preparation for the therapy
of immune deficiency conditions
US5767087
A pharmaceutical preparation for the therapy of immune
deficiency conditions comprising an active principle-a peptide of
the structure: H-L-Glu-L-Trp-OH and a pharmaceutically
acceptable vehicle.US5767087
Immunomodulating peptides and methods of
use
US6100380
This invention provides peptides of the formula R'-Glx-Glx-Lys-R''
in which Glx is Glu or Gln. In particular, this invention provides
the peptides Thr-Ala-Glu-Glu-Lys and Thr-Pro-Glu-Glu-Lys.
This invention also provides pharmaceutical compositions
comprising these peptides. The peptides of this invention are
useful for immunomodulation.US6100380
Pharmaceutical preparation for the therapy
of immune deficiency conditions
US5814611
A pharmaceutical preparation for the therapy of immune
deficiency conditions comprising an active principle-a peptide of
the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable
vehicle.US5814611
Pharmaceutical dipeptide compositions and
methods of use thereof: systemic toxicity
US5770576
Methods of treatment of subjects with systemic toxicity
by administering an R'-Glu-Trp-R'' pharmaceutical
preparation.US5770576
Method for treatment of purulent
inflammatory diseases
US5807830
This invention provides methods of treating purulent
inflammatory diseases by administering L-Glu-L-Trp or a
salt thereof.US5807830
Pharmaceutical dipeptide compositions and
methods of use thereof: immunodepressants
US5811399
Methods of treatment of subjects for decreasing cell
mediated autoimmunity or humoral autoimmunity by administering an
R'-Glu-Trp-R'' pharmaceutical preparation useful in
subjects having autoimmune diseases.US5811399
Pharmaceutical dipeptide compositions and
methods of use thereof
US5789384 // US6139862
Methods are provided for the therapy of immunodeficient,
immunodepressed or hyperactive immune states and for the treatment
of opportunistic infections in such states comprising
administering to a subject a pharmaceutically acceptable
composition comprising as an active ingredient the dipeptide L-Ile-L-Trp,
linear and cyclic monomers and polymers thereof, and/or
pharmaceutically acceptable salts thereof.US5789384 // US6139862
Tetrapeptide stimulating the fuctional
activity of hepatocytes, pharmacological substance on its
basis and the method of its application
US7101854
The invention refers to the field of medicine and may be
applied as a substance stimulating the functional activity of
hepatocytes, restoring the synthesis of non-specific proteins,
normalising metabolism activating the processes of proliferation
and differentiation of the liver cells. There is proposed a new
compound-tetrapeptide lysyl-glutamyl-aspartyl-alanine of the
general formula Lys-Glu-Asp-Ala [SEQ ID NO:1]. There is
proposed a pharmaceutical composition capable of stimulating the
functional activity of hepatocytes and a pharmaceutical peptide
substance containing as its active base a therapeutically
effective quantity of tetrapeptide of the formula Lys-Glu-Asp-Ala
[SEQ ID NO:1] or one of its salts intended for parenteral
administration.; There is proposed a method of stimulating the
functional activity of hepatocytes including therapeutic
administration to a patient of the pharmaceutical peptide
substance in doses 0.01-100 mug/kg of the body weight at least
once a day during a period required for attaining a therapeutic
effect.US7101854
Method of obtaining peptides with
tissue-specific activity and pharmaceutical compositions on
their basis
US2005004016
The invention refers to the field of chemistry and concerns the
method of obtaining peptides with tissue-specific activity by
targeted chemical synthesis. This invention can be employed in
medicine to obtain peptide-based pharmaceuticals normalising the
functions of various organs and functions. The method of obtaining
peptides proposed in this patent claim embraces quantitative amino
acid analysis of acetic extracts from tissues, selection on its
basis of two amino acids (Glu and Asp) prevailing in the studied
tissue, synthesis of the central link from these amino acids and
attachment to its N- and C-ends of the amino acids prevailing
among the remaining amino acids in the studied tissue. The
peptides obtained by the claimed method possess a tissue-specific
activity. There is proposed a pharmaceutical composition
possessing a tissue-specific activity and containing as its active
base one of the peptides obtained by the claimed method or its
salts and a pharmaceutically admissible carrier.US2005004016
Pharmaceutical preparation for the
therapy of immune deficiency conditions
US6136788
This invention is directed to water soluble salts of L-Glu-L-Trp.US6136788
Tetrapeptide stimulating functional
activity of neurons pharmacological agent based thereon and
method of use thereof
US7189701
Tetrapeptide L-alanyl-L-glutamyl-L-asparagyl-L-proline of the
general formula L-Ala-L-Glu-Asp-L-Pro is proposed as a
biologically active compound stimulating the functional activity
of neurones. The application of L-Ala-L-Glu-L-Asp-L-Pro
tetrapeptide in medicine is proposed for the preparation of a drug
stimulating the functional activity of neurones. There is proposed
a pharmacological agent, which contains as its active base an
effective amount of L-Ala-L-Glu-L-Asp-L-Pro tetrapeptide for its
salts of the amino acid group (acetate, hydrochloride, oxalate) or
its salts of carboxyl groups (the salts of sodium, potassium,
calcium, lithium, zinc, magnesium, and also the salts of organic
and inorganic cations-ammonium, triethylammonium). The agent is
proposed for parenteral, intranasal and oral administration. In
accordance with the invention, the method of stimulating the
functional activity of neurones consists in preventive and/or
therapeutic administration to the patient of the pharmacological
agent in doses 0.01 to 100 mug/kg of the body weight at least one
a day for a period necessary for attaining a therapeutic effect.US7189701
PHARMACEUTICAL LYSINE-CONTAINING
POLYPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
WO9409804
Pharmaceutical compositions and methods are provided for the
therapy of immunodeficient, immunodepressed or hyperactive immune
states and for the prevention and treatment of opportunistic
infections in such states comprising administering to a subject a
pharmaceutically acceptable composition comprising as an active
ingredient peptides having the formula R'-L-Glx-L-Glx-L-Lys-R"
and/or their pharmaceutically acceptable salts; wherein Glx is Gln
or Glu.WO9409804
PHARMACEUTICAL PENTAPEPTIDE COMPOSITIONS
AND METHODS OF USE THEREOF
WO9312810
Methods are provided for the therapy of immunodeficient,
immunodepressed or hyperactive immune states and for the
prevention and treatment of opportunistic infections in such
states comprising administering to a subject a pharmaceutically
acceptable composition comprising as an active ingredient the
pentapeptide L-Thr-L-Ala-L-Glx-L-Glx-L-Lys and/or its
pharmaceutically acceptable salts; wherein Glx is Gln or Glu.WO9312810
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND
METHODS OF USE THEREOF
WO9308815
Methods are provided for the therapy of immunodeficient,
immunodepressed or hyperactive immune states and for the
prevention and treatment of opportunistic infections in such
states comprising administering to a subject a pharmaceutically
acceptable composition comprising as an active ingredient the
dipeptide L-Glu-L-Trp, the cyclic monomer thereof, polymers
thereof of the formula H2N - [L-Glu-L-Trp]n - CO2H; cyclic
polymers thereof of formula (I) and their pharmaceutically
acceptable salts thereof, wherein n and m are independently >/=
2.WO9308815
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND
METHODS OF USE THEREOF
WO9217191
Methods are provided for the therapy of immunodeficient,
immunodepressed or hyperactive immune states and for the
prevention and treatment of opportunistic infections in such
states comprising administering to a subject a pharmaceutically
acceptable composition comprising as an active ingredient the
dipeptide L-Glu-L-Trp and/or its pharmaceutically
acceptable salts.WO9217191
PEPTIDE COMPOUND, STIMULATING FUNCTION OF
REPRODUCTIVE SYSTEM, PHARMACEUTICAL COMPOSITION AND METHOD OF
APPLICATION
RU2324703
FIELD: medicine; pharmacology. ^ SUBSTANCE: invention relates to
application of dipeptide with the general formula Nalpha-(gamma-L-glutamyl)-L-lysine,
for stimulation of function of the reproductive system by
modulating the neuroendocrine status in aging and in hypogonadal
condition. The pharmaceutical composition is invented, which
contains Nalpha-(gamma-L-glutamyl)-L-lysine, and the method of
stimulation of function of reproductive system. ^ EFFECT:
described compound efficiently stimulates function of reproductive
system. RU2324703
PHARMACEUTICAL WITH IMMUNOMODULATING
ACTIVITY
WO9503067
Pharmaceutical peptide preparations for inducing a
heightened state of anti-microbial cellular or humoral immunity in
a subject in need thereof consisting essentially of an L-Lys-L-Glu
or L-Glu-L-Trp preparation and a pharmaceutically
acceptable carrier.WO9503067
DIPEPTIDE INHIBITING ANGIOGENESIS IN
OPHTHALMOPATHOLOGY
WO02062371
The invention refers to medicine and concerns the
ophthalmologic application of dipeptide L-lysyl-L-glutamic
acid (L-Lys-L-Glu) as a preparation inhibiting
neovascularisation in ocular diseases. There is proposed the
application od L-Lys-L-Glu dipeptide or one of its salts as a
substance capable of angiogenesis inhibition in
ophthalmopathology. There is proposed a pharmaceutical preparation
for parenteral administration including the claimed dipeptide or
one of its salts in the amount, which is effective for the
prevention of and/or treatment for ophthalmopathology requiring
angiogenesis inhibition and which does not exceed 10 mu g in 1 m1
of a pharmaceutically admissible carrier. There is proposed a
method of ophthalmopathology treatment consisting in the
preventive and/or therapeutic administration to a patient of an
effective amount of the claimed pharmaceutical preparation for a
period required to attain a therapeutic effect with regard to the
character of the pathology development. The claimed pharmaceutical
preparation is active when administered in the does range of
0.1-100 mu g/kg of the body weight.WO02062371
TETRAPEPTIDE REGULATING PROSTATE FUNCTIONS
AND ITS COMPOSITIONS AND METHODS
WO02066497
The invention refers to the field of medicine and can be
applied for regulation prostate functions. Biologically active
tetrapeptide of the general formula Lys-Glu-Asp-Pro, a
pharmaceutical preparation capable of regulation the prostate
functions and containing an effective amount of Lys-Glu-Asp-Pro
tetrapeptide or one of its salts and a pharmaceutically admissible
carrier intended for the parenteral administration. In addition a
method of regulation the prostate functions, embraces
administration of the pharmaceutical preparation in the dose of
0.01-100 µg/kg of the body weight at least once a day during a
period required for attaining a therapeutic effect.WO02066497
TETRAPEPTIDE STIMULATING THE RETINAL
FUNCTION AND THE METHOD OF ITS APPLICATION
WO02090380
The invention relates to medicine and concerns the ophthalmologic
application of synthetic tetrapeptide Ala-Glu-Asp-Gly in
the treatment for eye diseases and pathologic states by means of
stimulating the retinal functions. The pharmaceutical peptide
substance is proposed to treat for diseases and pathologic states
accompanied by disturbed retinal functions and containing a
pharmaceutically admissible carrier and a therapeutically
effective quantity of tetrapeptide
alanyl-glutamyl-asparagyl-glycine or one of its pharmaceutically
admissible salts of the amino acid group (acetate, hydrochloride
or oxalate) or of carboxyl groups (salts of metals - sodium,
potassium, calcium, lithium, zinc, magnesium, as well as of
organic and inorganic cations - ammonium and triethylammonium).
There is claimed a method of treating for diseases and pathologic
states embracing a preventive or therapeutic administration to a
patient of the proposed pharmaceutical peptide substance
parenterally: parabulbarly and/or intramuscularly in the doses of
0.1-10 mu m/kg of the body weight at least once a day for a period
necessary to attain a therapeutic effect depending on the
character and severity of the pathologic process.WO02090380
AGENT PREVENTING DEGRANULATION OF MAST
CELLS
RU2030914
AGENT FOR PARADONTITIS TREATMENT
RU2084231
METHOD OF PREPARING SUBSTANCE RECOVERING REPRODUCTIVE FUNCTION FROM OVARIES
RU2056853
AGENT FOR SKIN CARE
RU2008894
METHOD OF EVALUATION OF PEPTIDES BIOLOGICAL ACTIVITY
RU1807399
METHOD OF TREATMENT OF PATIENTS HAVING ISCHURIA AFTER SURGICAL OPERATIONS ON ORGANS OF ABDOMEN AND PELVIS
RU2007175
METHOD OF OBTAINING IMMUNOSTIMULATOR
SU1187824
METHOD OF PRODUCING POLYPEPTIDES
SU1227198
METHOD OF TREATMENT OF GASTRIC ULCER AND DUODENAL ULCER
SU1105202
METHOD OF PROTEIN FOOD ADDITION PREPARING
RU2075944
AGENT SHOWING IMMUNOMODULATING ACTIVITY
RU2080120
AGENT RECOVERING RETINA EYE FUNCTION
RU2073518
AGENT SHOWING TONIC ACTION ON THE VEIN, BLADDER AND PROSTATE GLAND SMOOTH MUSCLE
RU2058780
Imunstimulejoss lidzeklis "timogen"
LV5407
PHARMACEUTICAL LYSINE-CONTAINING POLYPEPTIDE COMPOSITIONS AND THE USE THEREOF
HK1013622
Brain derived peptide complex
GB2213485
Thymus-gland preparation and method for producing same
GB2177402
Thymus-gland preparation and method for producing same
US5070076
SUPPORTING THERAPY REMEDY AND METHOD FOR ITS PRODUCTION FROM FROZEN SEA URCHIN SPAWN
RU2420212
AGENT FOR SUPPORTING THERAPY AND METHOD FOR MAKING AGENT OF FROZEN-DRIED URCHIN HARDROE
RU2414914
METHOD OF OBTAINING MEDICATION, WHICH HAS TISSUE-SPECIFIC ACTIVITY, AND MEDICATION, OBTAINED BY CLAIMED METHOD RU2415676
METHOD FOR PREPARING A MEDICAMENT FOR SUPPORTING THERAPY EXHIBITING TISSUE-SPECIFIC ACTIVITY, AND A MEDICAMENT OBTAINED THEREOF
EA010720
MEDICAMENT HAVING HETEROPROTECTIVE ACTIVITY AND METHOD FOR PREPARING THEREOF
EA010737
MEDICAMENT NORMALISING REPRODUCTIVE MALE FUNCTION AND METHOD FOR PREPARING THEREOF
EA010735
MEDICAMENT NORMALIZING FEMALE REPRODUCTIVE FUNCTION, AND METHOD FOR PREPARING THEREOF
EA010736
MEDICAMENT NORMALIZING THYROID GLAND FUNCTIONS AND METHOD FOR PREPARING THEREOF
EA010738
MEDICAMENT NORMALISING TONE OF URINARY BLADDER AND METHOD FOR PREPARING THEREOF
EA010722
MEDICAMENT NORMALIZING KIDNEY FUNCTIONS AND METHOD FOR PREPARING THEREOF
EA010723
MEDICAMENT NORMALIZING DRAIN FUNCTIONS AND METHOD FOR PREPARING THEREOF
EA010739
HEPATOPROTECTIVE MEDICAMENT AND METHOD FOR PREPARING THEREOF
EA010573
MEDICAMENT NORMALIZING BLOOD VESSEL FUNCTIONS, AND METHOD FOR PREPARING THEREOF
EA010734
PREPARATION NORMALIZING CARTILAGINOUS TISSUE, AND A METHOD FOR MANUFACTURING THEREOF
EA010724
PEPTIDE NORMALIZING NETABOLISM IN BONE AND CARTILAGINOUS TISSUES, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHOD FOR USE THEREOF
EA010574
PEPTIDE STIMULATING REGENERATION OF LIVER TISSUE, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF
EA010156
TETRAPEPTIDE REGULATING BLOOD GLUCOSE LEVEL IN DIABETES MELLITUS
UA85204
USE OF PEPTIDE PHARMACEUTICAL COMPOSITION AS A MEANS FOR TREATMENT OF HELICOBACTER PYLORI INDUCED GASTRODUODENAL DISEASES
EA021849
BIOACTIVE BEVERAGE
RU2377936
PHARMACEUTICAL COMPOSITION ON BASIS OF PEPTIDE POSSESSING ANTITUMORAL ACTION
RU2362579
PHARMACEUTICAL COMPOSITION BASED ON PEPTIDE REGULATING DISTURBANCES OF ANGIOGENESIS, AND WAY OF ITS APPLICATION
RU2363488
PEPTIDE PHARMACEUTICAL COMPOSITION NORMALISING URINATION, AND METHOD OF APPLICATION THEREOF
RU2367467
RU2030914
AGENT FOR PARADONTITIS TREATMENT
RU2084231
METHOD OF PREPARING SUBSTANCE RECOVERING REPRODUCTIVE FUNCTION FROM OVARIES
RU2056853
AGENT FOR SKIN CARE
RU2008894
METHOD OF EVALUATION OF PEPTIDES BIOLOGICAL ACTIVITY
RU1807399
METHOD OF TREATMENT OF PATIENTS HAVING ISCHURIA AFTER SURGICAL OPERATIONS ON ORGANS OF ABDOMEN AND PELVIS
RU2007175
METHOD OF OBTAINING IMMUNOSTIMULATOR
SU1187824
METHOD OF PRODUCING POLYPEPTIDES
SU1227198
METHOD OF TREATMENT OF GASTRIC ULCER AND DUODENAL ULCER
SU1105202
METHOD OF PROTEIN FOOD ADDITION PREPARING
RU2075944
AGENT SHOWING IMMUNOMODULATING ACTIVITY
RU2080120
AGENT RECOVERING RETINA EYE FUNCTION
RU2073518
AGENT SHOWING TONIC ACTION ON THE VEIN, BLADDER AND PROSTATE GLAND SMOOTH MUSCLE
RU2058780
Imunstimulejoss lidzeklis "timogen"
LV5407
PHARMACEUTICAL LYSINE-CONTAINING POLYPEPTIDE COMPOSITIONS AND THE USE THEREOF
HK1013622
Brain derived peptide complex
GB2213485
Thymus-gland preparation and method for producing same
GB2177402
Thymus-gland preparation and method for producing same
US5070076
SUPPORTING THERAPY REMEDY AND METHOD FOR ITS PRODUCTION FROM FROZEN SEA URCHIN SPAWN
RU2420212
AGENT FOR SUPPORTING THERAPY AND METHOD FOR MAKING AGENT OF FROZEN-DRIED URCHIN HARDROE
RU2414914
METHOD OF OBTAINING MEDICATION, WHICH HAS TISSUE-SPECIFIC ACTIVITY, AND MEDICATION, OBTAINED BY CLAIMED METHOD RU2415676
METHOD FOR PREPARING A MEDICAMENT FOR SUPPORTING THERAPY EXHIBITING TISSUE-SPECIFIC ACTIVITY, AND A MEDICAMENT OBTAINED THEREOF
EA010720
MEDICAMENT HAVING HETEROPROTECTIVE ACTIVITY AND METHOD FOR PREPARING THEREOF
EA010737
MEDICAMENT NORMALISING REPRODUCTIVE MALE FUNCTION AND METHOD FOR PREPARING THEREOF
EA010735
MEDICAMENT NORMALIZING FEMALE REPRODUCTIVE FUNCTION, AND METHOD FOR PREPARING THEREOF
EA010736
MEDICAMENT NORMALIZING THYROID GLAND FUNCTIONS AND METHOD FOR PREPARING THEREOF
EA010738
MEDICAMENT NORMALISING TONE OF URINARY BLADDER AND METHOD FOR PREPARING THEREOF
EA010722
MEDICAMENT NORMALIZING KIDNEY FUNCTIONS AND METHOD FOR PREPARING THEREOF
EA010723
MEDICAMENT NORMALIZING DRAIN FUNCTIONS AND METHOD FOR PREPARING THEREOF
EA010739
HEPATOPROTECTIVE MEDICAMENT AND METHOD FOR PREPARING THEREOF
EA010573
MEDICAMENT NORMALIZING BLOOD VESSEL FUNCTIONS, AND METHOD FOR PREPARING THEREOF
EA010734
PREPARATION NORMALIZING CARTILAGINOUS TISSUE, AND A METHOD FOR MANUFACTURING THEREOF
EA010724
PEPTIDE NORMALIZING NETABOLISM IN BONE AND CARTILAGINOUS TISSUES, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHOD FOR USE THEREOF
EA010574
PEPTIDE STIMULATING REGENERATION OF LIVER TISSUE, PHARMACEUTICAL COMPOSITION BASED THEREON AND USE THEREOF
EA010156
TETRAPEPTIDE REGULATING BLOOD GLUCOSE LEVEL IN DIABETES MELLITUS
UA85204
USE OF PEPTIDE PHARMACEUTICAL COMPOSITION AS A MEANS FOR TREATMENT OF HELICOBACTER PYLORI INDUCED GASTRODUODENAL DISEASES
EA021849
BIOACTIVE BEVERAGE
RU2377936
PHARMACEUTICAL COMPOSITION ON BASIS OF PEPTIDE POSSESSING ANTITUMORAL ACTION
RU2362579
PHARMACEUTICAL COMPOSITION BASED ON PEPTIDE REGULATING DISTURBANCES OF ANGIOGENESIS, AND WAY OF ITS APPLICATION
RU2363488
PEPTIDE PHARMACEUTICAL COMPOSITION NORMALISING URINATION, AND METHOD OF APPLICATION THEREOF
RU2367467